# A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM)

> **NCT02759107** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 142 (actual)

## Conditions studied

- Healthy
- Type 2 Diabetes Mellitus (T2DM)

## Interventions

- **DRUG:** Tirzepatide
- **DRUG:** Placebo
- **DRUG:** Dulaglutide

## Key facts

- **NCT ID:** NCT02759107
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-11
- **Primary completion:** 2017-06-26
- **Final completion:** 2017-06-26
- **Target enrollment:** 142 (ACTUAL)
- **Last updated:** 2024-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02759107

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02759107, "A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02759107. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*